SGLT2 Inhibitors May Cut Repeat Syncope in Type 2 Diabetes
A prospective, multicenter study suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiac autonomic dysfunction and reduce vaso-vagal syncope in patients with type 2 diabetes and prior syncope.
First Look
source https://www.medscape.com/viewarticle/968611?src=rss
First Look
source https://www.medscape.com/viewarticle/968611?src=rss
Comments
Post a Comment